Literature DB >> 12930381

Diagnosis and treatment of systemic mastocytosis: state of the art.

Peter Valent1, Cem Akin, Wolfgang R Sperr, Hans-P Horny, Michel Arock, Klaus Lechner, John M Bennett, Dean D Metcalfe.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 12930381     DOI： 10.1046/j.1365-2141.2003.04575.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  52 in total

1.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

2.  Systemic mastocytosis presenting with gastrointestinal, bone and skin involvement.

Authors:  Maria Rosignuolo; Marta Muscianese; Guglielmo Pranteda
Journal:  J Ultrasound       Date:  2014-04-08

3.  Two patients with osteoporosis: initial presentation of systemic mastocytosis.

Authors:  Marjolein L Donker; Nicolaas A Bakker; Wim J M Jaspers; Albert H Verhage
Journal:  J Bone Miner Metab       Date:  2008-02-27       Impact factor: 2.626

4.  Advanced mast cell disease: an Italian Hematological Multicenter experience.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Morena Caira; Michela Rondoni; Maria Teresa Van Lint; Anna Candoni; Bernardino Allione; Chiara Cattaneo; Laura Marbello; Cecilia Caramatti; Enrico Maria Pogliani; Emilio Iannitto; Fiorina Giona; Felicetto Ferrara; Rosangela Invernizzi; Rosa Fanci; Monia Lunghi; Luana Fianchi; Grazia Sanpaolo; Pietro Maria Stefani; Alessandro Pulsoni; Giovanni Martinelli; Giuseppe Leone; Pellegrino Musto
Journal:  Int J Hematol       Date:  2008-11-26       Impact factor: 2.490

5.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

6.  Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Authors:  Noria Harir; Cédric Boudot; Katrin Friedbichler; Karoline Sonneck; Rudin Kondo; Séverine Martin-Lannerée; Lukas Kenner; Marc Kerenyi; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Jean Gondry; Laurence Bénit; Isabelle Dusanter-Fourt; Kaïss Lassoued; Peter Valent; Richard Moriggl; Fabrice Gouilleux
Journal:  Blood       Date:  2008-06-25       Impact factor: 22.113

7.  Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Authors:  Barbara Peter; Karoline V Gleixner; Sabine Cerny-Reiterer; Harald Herrmann; Viviane Winter; Emir Hadzijusufovic; Veronika Ferenc; Karina Schuch; Irina Mirkina; Hans-Peter Horny; Winfried F Pickl; Leonhard Müllauer; Michael Willmann; Peter Valent
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

8.  Aggressive systemic mastocytosis of the liver with cholangitis.

Authors:  Nina Waldburger; Christian Rupp; Sabine Klinke; Kathrin Wieczorek; Daniel Gotthardt; Thomas Kirchner; Peter Schirmacher; Beate Katharina Straub
Journal:  Hepat Oncol       Date:  2015-11-06

9.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

10.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.